Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arrowhead Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR RPRX
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.